Objectives-To examine the appearance and resolution of left ventricular thrombi and to study the relation between thrombus and mortality during long term follow up after anterior myocardial infarction. Design-Ninety nine consecutive patients were prospectively studied until the last included patient had been followed for one year. Streptokinase and aspirin were used routinely, anticoagulants only after a decision by the attending physician. Echocardiography was performed within 3 d of admission, before discharge, and after one, three, and 12 months. Setting-Umeai University Hospital, a teaching hospital in Northern Sweden. Main outcome measures-Left ventricular thrombus, segmental myocardial function, and mortality during follow up. Results-Thirty patients (30%/6) had a thrombus on discharge. One month, three months, and 12 months after hospital discharge, the thrombus had resolved in 81%, 84%, and 90% of the patients, respectively.
The proportion of resolved thrombi at one month was high irrespective of whether anticoagulants were given (10/11, 91%) or not (12/16, 75/6), P = 0-4. New thrombi appeared in 12 patients after discharge and resolution and reappearance of thrombi continued during the follow up period. Patients who developed a thrombus during the hospital stay (n = 44, 44%) had more extensive myocardial dysfunction on discharge (P < 0.001) and significantly higher mortality during the follow up period than those without a thrombus (23% v 7%, P < 0.01). Conclusions-With routine thrombolytic and aspirin treatment of anterior myocardial infarction, left ventricular thrombi usually resolve during the first month after hospital discharge. Appearance and resolution of thrombi continue, however, in a 
% (n;n) % (n) % (n;n') % (n) % (n;n') % (n) heart failure, ruptured aortic aneurysm), one was a terminal malignant disease in combination with a cerebral infarct, and one was caused by a subdural haematoma. All four deaths in the patients without a thrombus were cardiovascular (sudden death, myocardial infarction), in one case in combination with a disseminated colon cancer. At the time of death two out of four patients in the non-thrombus group and four out of 10 patients in the thrombus group were treated with warfarin. Three patients had an ischaemic cerebral event during follow up and none of them was treated with warfarin. One patient had a right sided amaurosis fugax six months after inclusion. No thrombus was seen at echocardiography, but a severe stenosis in the right internal carotid artery was identified. The second patient had a cerebral infarct, verified by computed tomography, 17 months after inclusion. This patient was in the terminal stage of a malignant disease and died two weeks later. The third patient had a second myocardial infarct and a cerebral infarct during the same day, 10 months after inclusion in the study. The two last patients did not have a thrombus at the proceeding echocardiographic examination. Two patients had serious bleeding complications-one fatal and one non-fatal subdural haematoma. Both were treated with warfarin with anticoagulation levels within the therapeutic range. Figure 4 shows the cumulative survival during follow up for the entire study group and in patients with (n = 44) and without (n = 55) a diagnosed thrombus during the hospital stay. Patients with thrombus had a significantly higher mortality (P < 0-01), with a relative risk of death of 3-6 (95% confidence interval 1-2 to 10-8).
Discussion
Echocardiography is the method of choice for the serial identification of ventricular thrombi because of its wide availability, low cost, and non-invasive nature. 4 The method is accurate, with a sensitivity ranging between 77% and 100% and a specificity ranging between 8% and 100% when compared with findings at surgery or necropsy, or with platelet imaging. The accuracy of echocardiography is dependent of the image quality, and small thrombi, below the level of detection, may be present in areas of disturbed flow conditions. Potential diagnostic errors may, however, be minimised by strict adherence to echocardiographic criteria.'0 In this study we showed that the majority of left ventricular thrombi formed during the course of an anterior myocardial infarction resolve during the first three months after discharge (21/25, 84%). The proportion of thrombi reported to resolve during long term follow up in most previous studies was smaller, ranging between 20% and 58%.2 In one study oral anticoagulants were used routinely and resolution of thrombi were reported in 33% (4/14) after 12 months of follow up.' Treatment of left ventricular thrombi with oral anticoagulants has been examined in a controlled trial, and resolution of thrombi occurred in 59% and 88% of the patients after three and 12 months." The high proportion of thrombi resolving during follow up in our study may be associated with new treatment routines after myocardial infarction. Aspirin reduces thromboembolic complications in patients with atrial fibrillation'2 and may modify platelet deposition in some patients with left ventricular thrombi. '3 The use of thrombolytics and aspirin may hypothetically influence the thrombus structure and make it more susceptible to endogenous thrombolysis. Thirty patients had a thrombus at discharge (fig 1) and in 29% (12/42) a new thrombus appeared during follow up (fig 2) . In two previous reports the proportion of thrombi appearing after discharge was similar, 31% and 32%, respectively.' 3Thrombi formed after discharge constituted a large proportion of thrombi diagnosed after one month (55%), three months (64%), and one year (62%). Warfarin treatment seemed to prevent the formation of new thrombi after discharge, but the number of patients given warfarin was small. The dynamic process of resolution and reappearance of thrombi makes it difficult to use echocardiography to identify patients at risk for thromboembolic complications. If a thrombus has resolved at one examination, a new thrombus may well appear later on. Early thrombus formation (during the hospital period) has been reported to be associated with a high mortality.2 14 We found that a left ventricular thrombus diagnosed during the hospital stay is a marker for high mortality after discharge. In one previous study, early in-hospital mortality was higher in patients without a thrombus.5 However, several patients did not survive long enough for a ventricular thrombus to form. '5 In the same study no difference in myocardial infarct size was found in patients with and without a thrombus, in contrast to our findings and to several previous reports""-8 where patients with a thrombus had more extensive myocardial dysfunction. Three cerebral ischaemic events were recorded during the follow up period. The episode of amaurosis fugax was probably associated with a right sided internal carotid stenosis, whereas the other two events may have been embolic. It is, however, very difficult to differentiate between embolic and thrombotic events in patients with advanced atherosclerotic disease.'9 The incidence of cerebral embolisation was approximately 1% in large scale postinfarction trials investigating thrombolytic therapy. 20 21 Two serious bleeding episodes occurred, a reminder that warfarin may be associated with fatal complications, reported to occur in 1% to 4.8%. 22 We conclude that after treatment of anterior myocardial infarction with thrombolytics and aspirin most left ventricular thrombi resolves during the first month after discharge, but formation and resolution of thrombi continues during further follow up. The dynamic process of left ventricular thrombus formation and resolution makes it difficult to use echocardiography to identify patients at risk for thromboembolic complications. The formation of a thrombus during the hospital stay is associated with high mortality after discharge. Warfarin may prevent formation of new thrombi after hospital discharge, but the low incidence of cerebral embolisation after myocardial infarction and the risk of serious bleedings during warfarin treatment should be considered before instituting treatment with anticoagulants.
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